Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Howard

Showing results (361-370 of 429) with videos related to

Pageof 43
Sort By:
Arthritis and Rheumatism|August 1, 1996
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotypeF C Arnett, R F Howard, F Tan, et al.
Pediatric Neurology|May 29, 2024
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter StudyJohn F Brandsema, Matthew Ginsberg, Hideki Hoshino, et al.
Journal of Neuroimmunology|June 5, 2020
Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravisYingkai Li, Jeffrey T Guptill, Melissa A Russo, et al.
Vaccine|March 20, 2012
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in miceJoanne M Lumsden, Saule Nurmukhambetova, Jennifer H Klein, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
The American Journal of Tropical Medicine and Hygiene|October 15, 2014
Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patientsAsrat Bezuneh, Maowia Mukhtar, Asim Abdoun, et al.
Muscle & Nerve|May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Pageof 43

Showing results (361-370 of 429) with videos related to

Sort By:
Pageof 43
Arthritis and Rheumatism|August 1, 1996
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotypeF C Arnett, R F Howard, F Tan, et al.
Pediatric Neurology|May 29, 2024
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter StudyJohn F Brandsema, Matthew Ginsberg, Hideki Hoshino, et al.
Journal of Neuroimmunology|June 5, 2020
Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravisYingkai Li, Jeffrey T Guptill, Melissa A Russo, et al.
Vaccine|March 20, 2012
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in miceJoanne M Lumsden, Saule Nurmukhambetova, Jennifer H Klein, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
The American Journal of Tropical Medicine and Hygiene|October 15, 2014
Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patientsAsrat Bezuneh, Maowia Mukhtar, Asim Abdoun, et al.
Muscle & Nerve|May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Pageof 43